Alpha-1A adrenergic receptor activation increases inhibitory tone in CA1 hippocampus

Epilepsy Res. 2009 Apr;84(2-3):97-109. doi: 10.1016/j.eplepsyres.2008.12.007. Epub 2009 Feb 6.

Abstract

The endogenous catecholamine norepinephrine (NE) exhibits anti-epileptic properties, however it is not well understood which adrenergic receptor (AR) mediates this effect. The aim of this study was to investigate alpha(1)-adrenergic receptor activation in region CA1 of the hippocampus, a subcortical structure often implicated in temporal lobe epilepsies. Using cell-attached and whole-cell recordings in rat hippocampal slices, we confirmed that selective alpha(1)-AR activation increases action potential firing in a subpopulation of CA1 interneurons. We found that this response is mediated via the alpha(1A)-AR subtype, initiated by sodium influx, and appears independent of second messenger signaling. In CA1 pyramidal cells, alpha(1A)-AR activation decreases activity due to increased pre-synaptic GABA and somatostatin release. Examination of post-synaptic receptor involvement revealed that while GABA(A) receptors mediate the majority of alpha(1A)-adrenergic effects on CA1 pyramidal cells, significant contributions are also made by GABA(B) and somatostatin receptors. Finally, to test whether alpha(1A)-AR activation could have potential therapeutic implications, we performed AR agonist challenges using two in vitro epileptiform models. When GABA(A) receptors were available, alpha(1A)-AR activation significantly decreased epileptiform bursting in CA1. Together, our findings directly link stimulation of the alpha(1A)-AR subtype to release of GABA and somatostatin at the single cell level and suggest that alpha(1A)-AR activation may represent one mechanism by which NE exerts anti-epileptic effects within the hippocampus.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Action Potentials / drug effects
  • Action Potentials / physiology
  • Adrenergic alpha-Agonists / pharmacology
  • Adrenergic alpha-Antagonists / pharmacology
  • Animals
  • Animals, Newborn
  • Dose-Response Relationship, Drug
  • Evoked Potentials / drug effects
  • Evoked Potentials / physiology
  • GABA Antagonists / pharmacology
  • Hippocampus / cytology*
  • Hippocampus / drug effects
  • Hippocampus / physiology*
  • In Vitro Techniques
  • Inhibitory Postsynaptic Potentials / drug effects
  • Male
  • Neural Inhibition / drug effects
  • Neural Inhibition / physiology*
  • Neurons / drug effects
  • Neurons / physiology*
  • Organophosphorus Compounds / pharmacology
  • Patch-Clamp Techniques
  • Phenylephrine / pharmacology
  • Picrotoxin / pharmacology
  • Piperazines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, alpha-1 / metabolism*
  • Sodium Channel Blockers / pharmacology
  • Somatostatin / pharmacology
  • Tetrodotoxin / pharmacology
  • Time Factors

Substances

  • Adra1a protein, rat
  • Adrenergic alpha-Agonists
  • Adrenergic alpha-Antagonists
  • GABA Antagonists
  • Organophosphorus Compounds
  • Piperazines
  • Receptors, Adrenergic, alpha-1
  • Sodium Channel Blockers
  • Picrotoxin
  • 5-methylurapidil
  • Phenylephrine
  • Tetrodotoxin
  • Somatostatin
  • CGP 35348